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ttp://dx.doi.org/10.1016/j.ajpath.2012.12.031A dualistic pathway model of ovarian carcinoma (OvCA) pathogenesis has been proposed: type I OvCAs are
low grade, genetically stable, and relatively more indolent than type II OvCAs, most of which are high-
grade serous carcinomas. Endometrioid OvCA (EOC) is a prototypical type I tumor, often harboring
mutations that affect the Wnt and phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin
signaling pathways. Molecular and histopathologic analyses indicate type I and II OvCAs share over-
lapping features, and a subset of EOCs may undergo type I/type II progression accompanied by
acquisition of somatic TP53 or PIK3CAmutations. We used a murine model of EOC initiated by conditional
inactivation of the Apc and Pten tumor suppressor genes to investigate mutant Trp53 or Pik3ca alleles as
key drivers of type I/type II OvCA progression. In the mouse EOC model, the presence of somatic Trp53
or Pik3camutations resulted in shortened survival and more widespread metastasis. Activation of mutant
Pik3ca alone had no demonstrable effect on the ovarian surface epithelium but resulted in papillary
hyperplasia when coupled with Pten inactivation. Our ﬁndings indicate that the adverse prognosis
associated with TP53 and PIK3CA mutations in human cancers can be functionally replicated in mouse
models of type I/type II OvCA progression. Moreover, the models should represent a robust platform for
assessment of the contributions of Trp53 or Pik3ca defects in the response of EOCs to conventional and
targeted drugs. (Am J Pathol 2013, 182: 1391e1399; http://dx.doi.org/10.1016/j.ajpath.2012.12.031)Supported by National Cancer Institute grants RO1CA94172 (K.R.C.)
and RO1CA135554 (S.J.B.) and Department of Defense grant W81XWH-
10-2-0013 (K.R.C. and E.R.F.).Surgical pathologists continue to use traditional morphology-
based schemes for classifying ovarian carcinomas (OvCAs).
The schemes are based largely on the degree of resemblance
of the OvCAs to non-neoplastic epithelia in the female
genital tract. However, mounting clinicopathologic and
molecular data have led Kurman and Shih1 to propose
a “dualistic” model of OvCA pathogenesis in which OvCAs
are divided into two main categories, type I and type II.1e3
Type I OvCAs are suggested to be low-grade, relatively
indolent and genetically stable tumors that typically arise
from recognizable precursor lesions such as endometriosis or
so-called borderline (low malignant potential) tumors. Type I
OvCAs frequently harbor somatic mutations (eg, KRAS,
BRAF, CTNNB1, PTEN ) that dysregulate speciﬁc cell
signaling pathway factors or certain chromatin remodeling
complexes (eg, ARID1A). Type I OvCAs include most
endometrioid, clear cell, and mucinous carcinomas andstigative Pathology.
.low-grade serous carcinomas. In contrast, type II OvCAs are
proposed to be high-grade, biologically aggressive tumors
from their outset, with a propensity for metastasis from small-
volume primary lesions. Most type II OvCAs are high-grade
serous carcinomas, virtually all of which harbor mutant TP53
alleles.4 These tumors have a high level of chromosomal
instability.5 Although varied gene defects besides TP53
mutation have been identiﬁed in type II tumors, with the
exception of frequent genetic/epigenetic inactivation of
BRCA1/2 and NF1, RB1, and CDK12 mutations, each of the
somatic gene defects is found in a small fraction of
tumors.6e8 Notably, recent data suggest that many (and
perhaps most) high-grade serous carcinomas arise from
Wu et alepithelium in the fallopian tube, rather than the ovarian
surface epithelium (OSE).9e11 The identiﬁcation of precursor
lesions with p53 protein overexpression and clonal TP53
mutations in the fallopian tube epithelium (including “p53
signature lesions” and tubal intraepithelial carcinomas)
suggests TP53 mutation is an early event in the pathogenesis
of most type II OvCAs.12
The dualistic pathway model represents an advance in
conceptualizing OvCA pathogenesis, but the model is likely
an oversimpliﬁed view of a complex group of cancers. For
example, there are uncertainties about classiﬁcation of clear
cell carcinomas as type I versus type II, because their
molecular features are more in keeping with type I tumors,
but cytologic grade and clinical behavior are often more like
type II tumors.3 As another example, there is signiﬁcant
overlap in the morphologic and molecular features of high-
grade serous and high-grade endometrioid OvCAs (hereafter
referred to as EOCs) such that some pathologists now
default the majority of gland-forming or near-solid cyto-
logically high-grade OvCAs to the serous category and
consider “true” high-grade EOCs to be rare or nonexistent.13
In this scenario, all low-grade EOCs would be classiﬁed as
type I, and the category of high-grade EOCs would be
eliminated.
In a prior analysis of a substantial number of primary
human EOCs, we found that mutations predicted to activate
the canonical Wnt and phosphatidylinositol 3-kinase (PI3K)/
AKT/mammalian target of rapamycin (mTOR) signaling
pathways frequently co-occur in low-grade EOC, a prototyp-
ical type I OvCA.14 Activation of Wnt signaling typically
occurs as a consequence of oncogenicCTNNB1mutations, or
rarely bi-allelic APC inactivation, whereas PI3K/AKT/
mTOR signaling is usually activated because of PTEN inac-
tivation and/or oncogenic PIK3CA mutations. Notably, we
identiﬁed 4 of 21 tumors with gene expression and/or muta-
tional proﬁles like type I EOCs, but the tumors had also
acquired TP53 mutations, suggesting type I/type II
progression may occur in a sizeable subset (nearly 20%) of
EOCs.14 Similarly, we identiﬁed four EOCswithmutations in
both PTEN and PIK3CA, rather than a single mutation dys-
regulating PI3K/AKT/mTOR signaling. Importantly, TP53
mutation has been associatedwith adverse outcome inwomen
with endometrioid carcinomas of the endometrium and
ovary,15e18 and PIK3CA mutation has been linked to poor
outcome in patients with several types of cancer, including
carcinomas of the endometrium, breast, and colon.19e22 The
effect of PIK3CAmutations on the prognosis of patients with
OvCA is unclear, because some studies have shown an
adverse effect on outcome, whereas others showed no or even
a favorable effect.23e25 The notion that type II tumors can
progress from type I tumors is not unique to EOCs. Indeed,
type I/type II progression in serous carcinomas has also
been described and is often associated with acquisition of
TP53 mutation.26e29
We previously described a murine model for type I
human EOC in which concurrent dysregulation of Wnt and1392PI3K/AKT/mTOR signaling is achieved through condi-
tional inactivation of the Apc and Pten tumor suppressor
genes in the OSE.14 In this model, ovarian bursal injection
of recombinant adenovirus expressing Cre recombinase
(AdCre) in Apcﬂox/ﬂox;Ptenﬂoxf/ﬂox mice results in the devel-
opment of EOC-like tumors with complete penetrance. The
purpose of the present study was to determine the effect of
mutant Trp53 and Pik3ca on the Apc/;Pten/ murine
EOC tumor phenotype as models of type I/type II
progression.
Materials and Methods
Strains of Transgenic Mice
In Apcﬂox/ﬂox;Ptenﬂox/ﬂox mice, conditional inactivation of the
Apc and Pten tumor suppressor genes in the mouse OSE
(MOSE) results in ovarian tumor development with 100%
penetrance.14 Trp53 LSL-R172H/þ (01XM2), Trp53R270H/þ
(01XM1), andTrp53ﬂox/ﬂox (01XC2)micewerepurchased from
theNational Cancer Institute (Bethesda,MD)mouse repository
and cross-bred with Apcﬂox/ﬂox;Ptenﬂox/ﬂox mice to generate the
respective triple transgenic strains. Pik3caLSL-E545K/þ mice
were developed in which a conditional mutant (LSL-E545K)
allele is knocked into one of the endogenous Pik3ca loci.30
Cre-mediated deletion of a lox-STOP-lox cassette inserted
upstream of the ﬁrst coding exon activates expression of
Pik3caE545K from the endogenous locus. Themicewere crossed
with Apcﬂox/ﬂox;Ptenﬂox/ﬂox mice to generate triple transgenic
Apcﬂox/ﬂox;Ptenﬂoxﬂox;Pik3ca LSL-E545K/þmice. All strains were
maintained on a mixed C57BL/6;FVB;129 background.
Induction of Murine Ovarian Tumors
For tumor induction, 5  107 plaque-forming units of
replication-incompetent AdCre (purchased from the
University of Michigan’s Vector Core) with 0.1% Evans
blue (Sigma-Aldrich, Indianoplis, IN) were injected into the
right ovarian bursal cavities of 6- to 10-week-old female
mice as previously described.14,31 In each mouse, the left
ovarian bursa was not injected and served as control.
Mouse Histopathology and Immunohistochemistry
All tumor-bearing mice were euthanized per the Committee
on Use and Care of Animals guidelines at the University of
Michigan for end-stage illness and humane endpoints and
then examined at necropsy. The genital tract and other major
organs were collected from each mouse, ﬁxed in 10% (v/v)
buffered formalin, and embedded in parafﬁn. H&E-stained
tissue sections were evaluated by a board-certiﬁed surgical
pathologist with expertise in gynecologic cancer diagnosis
(K.R.C). Immunohistochemical staining was performed
with standard methods; antigeneantibody complexes were
detected with the avidin-biotin peroxidase method with the
use of 3,30-diaminobenzidine as the chromogenic substrate.ajp.amjpathol.org - The American Journal of Pathology
Models of Ovarian Cancer ProgressionAntibodies used in this study include rat anti-cytokeratin 8
(CK8, #TROMA1;Developmental StudiesHybridomaBank,
University of Iowa); rabbit anti-p53 (Vector Laboratories Inc.,
Burlingame, CA), rabbit antiephospho-AKT (Ser473; #4060;
Cell Signaling Technology, Inc., Danvers, MA), rabbit anti-
PTEN (clone 138G6, #9559; Cell Signaling Technology,
Inc.), mouse antieb-catenin (Transduction Laboratories,
Lexington, KY), goat antieE-cadherin (R&D Systems,The American Journal of Pathology - ajp.amjpathol.orgMinneapolis, MN), rabbit antieWT-1 (sc-192; Santa Cruz
Biotechnology, Inc., Dallas, TX), and rabbit anti-PAX8
(NBP1-74734; Novus Biologicals, Littleton, CO).
Genotyping and Recombination Analysis of Mouse
Tumors
Genomic DNAwas isolated from tail snips, ovarian tumors, or
other organs, andPCRwasperformedwith primers that allowed
distinction between endogenous, genetically modiﬁed, and
recombined alleles (primer sequences are available on request).
Representative data are shown in Supplemental Figure S1.
Statistical Analysis
Graphs were constructed and statistical functions were
analyzed with GraphPad Prism version 5 (GraphPad Soft-
ware Inc., La Jolla, CA). Kaplan-Meier survival curves were
compared separately for each experimental pair by log-rank
(Mantel-Cox) tests; P < 0.05 was considered statistically
signiﬁcant. Metastasis between groups was compared with
a c2 contingency table test for independence.
Results
More Aggressive Phenotype of Murine Apc/;Pten/
Ovarian Tumors with the Addition of Somatic Missense
Trp53 Mutations
Somaticmissense substitutions in the TP53 genewhich result in
the R175H and R273H alleles are among the most frequently
identiﬁed p53mutations in human cancers; both the R175H and
R273H TP53 alleles have been studied for their loss-of-function
effects on the transcription activity of p53, as well as for
potential gain-of-function effects. In OvCAs, R273H, R248W,
and R175H are the most common missense TP53 mutations
(Catalogueof SomaticMutations inCancer; http://www.sanger.
ac.uk/perl/genetics/CGP/cosmic?actionZgene&lnZTP53).
As ameans ofmodeling type I to type II progression of EOCs,
we introduced the murine equivalents of the R273H (R270H)
and R175H (R172H) mutations into Apcﬂox/ﬂox;Ptenﬂoxﬂoxmice.
Speciﬁcally, Apcﬂox/ﬂox;Ptenﬂoxﬂox mice were crossbred with
mice that carried a conditionalmutantTrp53LSL-R172H allele32 or
constitutive mutant Trp53R270H allele33 to yield Apcﬂox/ﬂox;
Ptenﬂoxﬂox;Trp53LSL-R172H/þ and Apcﬂox/ﬂox;Ptenﬂoxﬂox;Figure 1 The phenotype of murine Apc/;Pten/ ovarian tumors is
more aggressive with the addition of missense Trp53 mutations. Kaplan-Meier
survival curves of Apcﬂox/ﬂox;Ptenﬂoxﬂox;Trp53 LSL-R172H/þ mice (n Z 11) and
Apcﬂox/ﬂox;Ptenﬂoxﬂox littermate controls (n Z 9) (A) and Apcﬂox/ﬂox;
Ptenﬂoxﬂox;Trp53 R270H/þ mice (n Z 11) and Apcﬂox/ﬂox;Ptenﬂoxﬂox littermate
controls (n Z 10) (B) after ovarian bursal AdCre injection. H&E-stained
sections of Apc/;Pten/;Trp53R172H/þ ovarian tumors showing glandular
epithelial differentiation admixed (C) with more poorly differentiated spindle-
cell areas (D). Representative metastases on the surface of the liver (E) and
kidney (F; aggregate of metastatic tumor cells indicated by an arrow) are
shown. Immunohistochemical stainingof p53 in representative ovarian tumors
arising in Apcﬂox/ﬂox;Ptenﬂoxﬂox;Trp53 LSL-R172H/þ (G) and Apcﬂox/ﬂox;Ptenﬂoxﬂox;
Trp53 R270H/þ (H) mice. Scale bars: 100 mm (CeH).
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Wu et alTrp53R270H/þmice. Ovarian tumors were induced by injection
of AdCre into the right ovarian bursa, and tumor-bearing mice
weremonitored for severalweeks thereafter.MicewithApc/;
Pten/ ovarian tumors also expressing R172H or R270H
mutant p53 had signiﬁcantly shorter survival than littermate
mice with Apc/;Pten/ tumors that had wild-type Trp53
alleles (PZ 0.0001 andPZ 0.0227, respectively) (Figure 1, A
and B). Similar to the Apc/;Pten/ ovarian tumors we
previously described, tumors expressing mutant p53 showed
areas with glandular, overtly epithelial differentiation admixed
with more poorly differentiated spindle-cell areas (Figure 1, C
and D). Metastatic carcinoma, represented by small tumor
implants on the surface of abdominalorgans, including liver and
kidney (Figure 1, E and F), was identiﬁed more frequently in
mice expressing R172H mutant p53 than Apcﬂox/ﬂox;Ptenﬂoxﬂox;
Trp53þ/þ tumor-bearing littermates (PZ 0.025). Microscopic
lung metastases were observed only in mice whose tumors
expressed mutant p53, albeit in a small fraction. Immunohis-
tochemical staining showed nuclear accumulation of p53 in the
tumor cells expressing either the R172H or R270H mutant
(Figure 1, G and H); in some cases p53 overexpression was
focal and in others more diffuse. Data collected from ovarian
tumor-bearing Apcﬂox/ﬂox;Ptenﬂoxﬂox;Trp53LSL-R172H/þ and
Apcﬂox/ﬂox;Ptenﬂoxﬂox;Trp53R270H/þ mice are summarized in
Table 1.
Mice Bearing Apc/;Pten/;Trp53/ Tumors Have
the Shortest Survival and Frequently Develop Bulky
Metastatic Disease
Because null and missense Trp53 mutations have been
shown to have different effects on the tumor phenotype in
several mouse model systems34 and roughly 10% of TP53
mutations in human EOCs result in loss of p53 protein
expression (ie, nonsense, insertion, deletion; http://www.
sanger.ac.uk/search/s), we also wished to test the effects
of Trp53 deletion in the Apc/;Pten/ model of EOC.
Notably, in humans, distant metastases are nearly eightfold
more common in patients with OvCAs that carry TP53 null
mutations compared with those with missense mutations.35Table 1 Effects of Missense and Null Trp53 Mutations on the Apc/;
Trp53 genotype Tumor size (mm3) Metastasis (n/N) P*
LSL-R172H/þ 4752.7  1767.8 8/11
0.025
þ/þ 4632.8  2178.6 2/9
R270H/þ 4331.2  1383.3 4/11
0.757
þ/þ 4838.2  1868.1 3/10
ﬂox/ﬂox 3068.7  877.0 9/9
ﬂox/þ 3137.6  1536.9 6/8 0.016
þ/þ 2422.8  1351.7 2/6
*Determined by c2 test.
yDetermined by log-rank test for median survival.
ﬂox, ﬂox (del ex2-10).
1394Apcﬂox/ﬂox;Ptenﬂoxﬂox mice were crossed with mice harbor-
ing conditional knockout (Trp53ﬂox) alleles, allowing Cre-
mediated deletion of Trp53 exons 2 through 10.36 Ovarian
tumors were induced in Apcﬂox/ﬂox;Ptenﬂoxﬂox;Trp53ﬂox/ﬂox as
well as Apcﬂox/ﬂox;Ptenﬂoxﬂox;Trp53ﬂox/þ and Apcﬂox/ﬂox;
Ptenﬂoxﬂox;Trp53þ/þ littermates with bursal AdCre injection.
Mice with Apc/;Pten/;Trp53/ ovarian tumors had
signiﬁcantly reduced survival than mice with Apc/;
Pten/ tumors in which one or both Trp53 alleles were
intact (P Z 0.0006 and P Z 0.0004, respectively). No
signiﬁcant difference in survival was observed between
mice whose tumors had Cre-mediated deletion of one Trp53
allele compared with mice with two intact alleles (P Z
0.3482) (Figure 2A and Table 1). At necropsy, all of the
tumor-bearing Apcﬂox/ﬂox;Ptenﬂoxﬂox;Trp53ﬂox/ﬂox mice had
grossly visible abdominal metastases (Figure 2B). Repre-
sentative photomicrographs of tumors arising in Apcﬂox/ﬂox;
Ptenﬂoxﬂox;Trp53ﬂox/ﬂox and Apcﬂox/ﬂox;Ptenﬂoxﬂox;Trp53ﬂox/þ
mice are shown in Figure 2, C and D. The distribution of
tumor growth outside of the ovary was similar to that seen in
patients with OvCA stage IV disease, because some mice
showed deep extension of tumor into the parenchyma of
liver (Figure 2E) and/or kidney, and one mouse had
metastasis to the lung (Figure 2F). Metastatic carcinoma
was observed signiﬁcantly less frequently in tumor-bearing
Apcﬂox/ﬂox;Ptenﬂoxﬂox;Trp53þ/þ littermates (P Z 0.016).
Apc/;Pten/;p53/ ovarian tumors and their metastases
were poorly differentiated, but the epithelial components
showed strong expression of E-cadherin (Figure 2G) and
cytokeratin 8 (not shown). As expected, the tumor cells
showed complete absence of p53 expression (Figure 2H).
EOC Development in Mice Requires Combined Defects
in Canonical Wnt and PI3K/AKT/mTOR Signaling, Even
in the Presence of Mutant p53
Studies of human high-grade serous OvCAs and precursor
lesions in the fallopian tube suggest that TP53 mutations
occur early and may be required for their development. In
contrast, only a subset (z20%) of type I EOCs withPten/ Tumor Phenotype
Lung
metastasis (n/N)
Median
survival (days) Py
1/11 57
0.0001
0/9 76
1/11 71
0.0227
0/10 75
1/9 57 ﬂox/ﬂox vs ﬂox/þ, 0.0006
0/8 64 ﬂox/ﬂox vs þ/þ, 0.0004
0/6 69.5 ﬂox/þ vs þ/þ, 0.3482
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Figure 2 Mice bearing Apc/;Pten/;p53/ tumors have shortest
survival and develop bulky metastatic disease.A: Kaplan-Meier survival curves
ofApcﬂox/ﬂox;Ptenﬂoxﬂox;Trp53 ﬂox/ﬂox (nZ 9),Apcﬂox/ﬂox;Ptenﬂoxﬂox;Trp53ﬂox/þ
(nZ 8), and Apcﬂox/ﬂox;Ptenﬂoxﬂox;Trp53þ/þ (nZ 6)mice after ovarian bursal
injection of AdCre. B: Image of representative tumor-bearing Apcﬂox/ﬂox;
Ptenﬂoxﬂox;Trp53 ﬂox/ﬂox mouse showing grossly visible ovarian tumor (white
star) and abdominal metastasis (black star). Representative photomicro-
graphs of H&E-stained sections showing primary ovarian tumor from Apcﬂox/ﬂox;
Ptenﬂoxﬂox;Trp53 ﬂox/ﬂox mouse (C), primary ovarian tumor from Apcﬂox/ﬂox;
Ptenﬂoxﬂox;Trp53 ﬂox/þ mouse (D), parenchymal liver metastasis (E), and lung
metastasis (F) in tumor-bearing Apcﬂox/ﬂox;Ptenﬂoxﬂox;Trp53ﬂox/ﬂox mice.
Immunohistochemical stains showing strong expression of E-cadherin (G) and
absence of p53 expression (H) in sections from a representative Apc/;
Pten/;p53/ ovarian tumor. Scale bars: 100 mm (CeH).
Models of Ovarian Cancer Progressioncanonical Wnt and PI3K/AKT/mTOR signaling pathway
defects also have TP53 mutations, suggesting that mutant
p53 is not required for EOC development but may be asso-
ciated with type I to type II progression. In previous studies,
we showed that EOCs fail to develop unless both Wnt and
PI3K/AKT/mTOR signaling pathways are concomitantly
dysregulated. Speciﬁcally, no tumors formed after ovarian
bursal AdCre injection in any of 61 Apcﬂox/ﬂox or 63 Ptenﬂox/ﬂox
mice.14 Here, we wished to test whether Trp53 point mutations
(R172H or R270H) could cooperate with dysregulation of
either canonical Wnt or PI3K/AKT/mTOR signaling in initi-
ating EOCs in our mouse model. Ovarian bursal AdCre injec-
tion was performed in Apcﬂox/ﬂox;Ptenﬂox/þ;Trp53LSL-R172H/þThe American Journal of Pathology - ajp.amjpathol.org(nZ 2) and Apcﬂox/þ;Ptenﬂox/ﬂox;Trp53R270H/þ (nZ 2) mice,
and animals were monitored for up to 9 months. Although
only a small number of mice with each genotype were tested,
none of the mice developed ovarian tumor, further supporting
the conclusion that dysregulation of both Wnt and
PI3K/AKT/mTOR signaling is required for murine EOC
development, even in the presence of mutant p53.
Mice with Apc/;Pten/;Pik3caE545K/þ EOCs Have
Shortened Survival Compared with Mice with EOCs
Lacking Mutant Pik3ca
In our previous analysis of 21 human EOCs with type I
OvCA gene expression and mutational proﬁles, 7 had
mutations predicted to dysregulate PI3K/AKT/mTOR
signaling, including 3 EOCs that had inactivating PTEN
mutations in addition to activating PIK3CA mutations in
exons 9 or 20.14,37 Because frequent mutations in PIK3CA
exons 1 to 7 have been reported in endometrial adenocar-
cinomas,38 we subsequently evaluated these exons in our set
of EOCs. One additional tumor (which also had mutant
PTEN ) was found to harbor two mutations in PIK3CA exon
1 (R88Q and K111N; Cho laboratory). Both of these have
previously been reported as gain-of-function muta-
tions.39e41 To determine effects of mutant Pik3ca on our
murine EOC tumor phenotype, Apcﬂox/ﬂox;Ptenﬂoxﬂox mice
were crossed with mice in which a conditional mutant (LSL-
E545K) allele is knocked into one of the endogenous Pik3ca
loci. Ovarian bursal AdCre injection was used to induce
tumors in Apcﬂox/ﬂox;Ptenﬂoxﬂox;Pik3caLSL-E545K/þ and
Apcﬂox/ﬂox;Ptenﬂoxﬂox;Pik3caþ/þ littermates. Mice with Apc/;
Pten/;Pik3caE545K/þ tumors (n Z 11) had signiﬁcantly
shorter survival (P Z 0.0003) and more frequent ascites and
metastasis than littermate controls (n Z 11), with Apc/;
Pten/ tumors lacking mutant Pik3ca (Figure 3A and
Table 2). The addition of mutant Pik3ca had no appreciable
effect on tumor morphology (Figure 3, B and C). As observed
by Liang et al42 and Kinross et al,43 activation of mutant
Pik3ca alone (nZ 4) was insufﬁcient to initiate tumors in the
MOSE. However, in contrast to these other studies, we did not
observe signiﬁcant epithelial hyperplasia in mice expressing
only mutant Pik3ca in the MOSE (Figure 4A). Ovarian bursal
injection of AdCre in Ptenﬂox/ﬂox;Pik3caLSL-E545K/þ mice
resulted in the development of nonepithelial hamartoma-like
tumor masses (to be reported separately) in 9 of 11 mice
similar to those reported in the soft tissue of humans with PTEN
hamartoma tumor syndromes.44 In addition, all 11 Ptenﬂox/ﬂox;
Pik3caLSL-E545K/þ mice displayed micropapillary proliferation
of the MOSE that resembled low-grade (type I) serous carci-
noma between 9 and 30 weeks after AdCre administration
(Figure 4, B and C). The hyperplastic epithelium showed strong
expression of CK8, WT1, and PAX8, consistent with a Mulle-
rian epithelial rather than mesothelial proliferation (Figure 4, D,
E, and F). In addition, as expected, the hyperplastic epithelial
cells were negative for Pten (Figure 4G) but showed elevated
expression of p-AKT (Figure 4H). The changes in our1395
Figure 3 Mice with Apc/;Pten/;Pik3caE545K EOCs have shortened
survival. A: Kaplan-Meier survival curve of tumor-bearing Apcﬂox/ﬂox;
Ptenﬂoxﬂox;Pik3ca E545K/þ (n Z 11) and Apcﬂox/ﬂox;Ptenﬂoxﬂox (n Z 11)
mice. Photomicrographs of representative primary OvCAs from Apcﬂox/ﬂox;
Ptenﬂoxﬂox (B) and Apcﬂox/ﬂox;Ptenﬂoxﬂox;Pik3caE545K/þ (C) mice. Scale
bars: 100 mm (B and C).
Wu et alPtenﬂox/ﬂox;Pik3caLSL-E545K/þ mice are similar to the hyper-
proliferative surface epithelium observed byKinross et al43 after
expression of Pik3caH1047R in the MOSE.
Mice with several other combinations of mutant Apc,
Pten, and Pik3ca alleles were also tested for their ability to
form ovarian tumors after bursal AdCre injection (Table 2).
In previous work, we showed that none of the 20 Apcﬂox/ﬂox;
Ptenﬂox/þ mice and only 1 of the 20 Apcﬂox/þ;Ptenﬂox/ﬂox
mice developed OvCA after AdCre injection.14 In this
study, we found that AdCre induced OvCAs in two of ﬁve
Apcﬂox/þ;Ptenﬂoxﬂox;Pik3caLSL-E545K/þ mice, whereas the other
three mice displayed hamartoma-like masses and micro-
papillary proliferation of the MOSE similar to that observed in1396Ptenﬂoxﬂox;Pik3caLSL-E545K/þ mice. The carcinomas were not
accompanied by hamartomatous lesions, presumably because
the carcinomas progressed rapidly and may have overgrown
early hamartomatous lesions. Similarly, four of six Apcﬂoxﬂox;
Ptenﬂox/þ;Pik3caE545K/þ mice developed OvCAs after AdCre
injection. None of the Ptenﬂox/þ;Pik3caLSL-E545K (n Z 3) or
Trp53R270/þ;Pik3caLSL-E545K (nZ 4) mice developed ovarian
surface epithelial alterations or tumors after AdCre injection
within the 40-week surveillance period. Hence, tumor
formation is most efﬁcient when both alleles of Apc and Pten
are inactivated, but addition of mutant Pik3ca increases the
frequency of tumor formation when one copy of either Apc or
Pten is intact.
Discussion
Understanding differences in the biology and genetics of
type I versus type II OvCAs is considered critical for
identifying new therapeutic strategies that will improve
outcome for patients with OvCA. Type I OvCAs are char-
acterized as low-grade, slow-growing tumors that are more
resistant to conventional chemotherapy but more likely to be
responsive to hormonal therapy than their high-grade (type II)
counterparts.45 The type I tumors have a more favorable
prognosis, largely because many are diagnosed when the
tumors are conﬁned to the ovary and curable with surgical
removal. It is important to emphasize that women with
advanced-stage type I tumors have a poor prognosis. In
a recent study of >600 consecutive OvCAs, no signiﬁcant
difference in progression-free or overall survival was
observed between women with advanced-stage type I versus
type II tumors.46 Because many women with type I tumors
will die of their disease, understanding the molecular events
underlying type I tumor progression and metastasis and how
type I and type II tumors differ are important goals. The
dualistic model originally argued for the existence of two
distinct pathogenetic pathways for OvCA development, but
molecular and histopathologic analyses suggest that the two
pathways are not mutually exclusive and that a sizeable
subset of endometrioid (and smaller subset of serous)
carcinomas may undergo type I/type II progression,
perhaps associated with acquisition of TP53 and/or PIK3CA
mutations. The murine model systems described herein
provide support for the adverse prognostic effects of TP53
and PIK3CA mutations observed in human endometrial,
ovarian, and other types of carcinomas.
The murine EOCs that develop in our model system show
morphologic features similar to their human counterparts,
including distinct gland formation and occasional foci of
squamous differentiation. Unlike typical primary human
EOCs, themurine tumors also show areas of less-differentiated
cells with spindle-cell morphology, possibly representing
epithelial-mesenchymal transition.14 It is difﬁcult to compare
survival of tumor-bearingmice with that of patients with EOC,
in part because women with EOC are usually treated with
surgical resection (with or without chemotherapy), and thisajp.amjpathol.org - The American Journal of Pathology
Table 2 Effects of Mutant Pik3ca on the Phenotype of Ovarian Tumors with Mutant Pten, Apc, and/or Trp53 Alleles
Genotype No. Normal
MOSE
proliferation Carcinoma
Peritoneal
metastasis
Lung
metastasis
Ptenþ/þ;Pik3caLSL-E545K/þ 4 4
Ptenﬂox/þ;Pik3caLSL-E545K/þ 3 3
Pik3caLSL-E545K/þ;Trp53R270H/þ 4 4
Ptenﬂox/ﬂox;Pik3caLSL-E545K/þ 11 11
Ptenﬂox/ﬂox;Pik3caLSL-E545K/þ;Trp53LSI-R172H/þ 5 5
Apcﬂox/þ;Ptenﬂox/ﬂox;Pik3caLSL-E545K/þ 5 3 2
Apcﬂox/ﬂox;Ptenﬂox/þ;Pik3caLSL-E545K/þ 6 2 4
Apcﬂox/ﬂox;Ptenﬂox/ﬂox;Pik3caLSL-E545K/þ 11 11 7 1
Apcﬂox/ﬂox;Ptenﬂox/ﬂox 11 11 4
Models of Ovarian Cancer Progressioninterventionmakes it nearly impossible todetermine the natural
history of untreated EOC in humans. Nonetheless, it is
important to note that tumors arising in our model are usually
quite large before mice require euthanasia, and we have per-
formed studies showing that mice can be “cured”with surgical
resection several weeks after tumor initiation with AdCre
injection (Cho laboratory, unpublished data), suggesting that
metastasis occurs relatively late in the biological progression of
disease. This is similar to the behavior of type I human tumors,
which often become large enough for clinical detection before
metastasis has occurred. In contrast, type II tumors are believed
to acquire metastatic potential much earlier, often when the
primary tumor is small and clinically undetectable. Given these
features, we believe the murine tumors recapitulate many, but
by no means all, features of human EOCs. Importantly, the
model system is also valuable for studying the relative contri-
bution of speciﬁc genetic alterations to tumor progression.
The work presented here is illustrative of this latter point,
particularly given our speciﬁc focus on the same gene/pathway
defects that are present in human EOCs.
We note with interest that different groups have observed
variable effects of expressing mutant Pik3ca in the MOSE.The American Journal of Pathology - ajp.amjpathol.orgAlthough Kinross et al43 and Liang et al42 found that
expression of activated Pik3ca alone resulted in MOSE
hyperplasia, expression of Pik3caE545K did not cause
striking epithelial proliferation in our model system when
Pten function remained intact. The phenotypic differences
among the three studies could reﬂect different genetic
backgrounds of the mice, differences in the methods with
which Cre-mediated recombination is induced in the MOSE,
or the speciﬁc mutant Pik3ca alleles evaluated. Although
Kinross et al43 also used bursal injection of AdCre to induce
Cre-mediated activation of mutant Pik3ca in the MOSE,
they used a mutation (H1047R) that affects the kinase
domain of the p110a protein. Liang et al42 generated mice
in which the MISIIR promoter was used to drive expression
of Pik3ca with the avian src myristoylation sequence added
to the N-terminus, resulting in constitutive expression of
activated p110a.30 Mice in both of these studies developed
epithelial hyperplasia but no carcinomas within the 18-month
monitoring period. The E545K mutation that we used is in the
helical domain of p110a. Helical domain and kinase domain
mutations of PIK3CA induce gain of function by different
mechanisms.47 The functional consequences of helical domainFigure 4 Pik3caE545K induces epithelial hyper-
plasia in the context of Pten loss and in combi-
nation with other genes. A: Normal-appearing
ovary from Pik3caLSL-E545K mouse 40 weeks after
AdCre injection. B: Ovary from Ptenﬂox/ﬂox;Pik3-
ca
LSL-E545K
mouse 9 weeks after AdCre injection
showing focal papillary proliferation of surface
epithelium (H&E). C: Higher magniﬁcation photo-
micrograph of boxed area in B. Immunohisto-
chemical stains showing expression of CK8 (D),
WT1 (E), and PAX8 (F) in the hyperplastic
epithelial cells. Additional immunohistochemical
stains conﬁrming loss of Pten (G) and increased
pAkt expression (H) in the hyperplastic epithe-
lium. Scale bars: 100 mm (AeH).
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Wu et almutations do not depend on binding to p85 but require
interaction with RAS-GTP, whereas function of the kinase
domain mutants depend on the interaction with p85, but not
RAS-GTP binding. Recently, Ross et al48 showed that the
effects of mutant PIK3CA are both cell type and mutation
speciﬁc. Speciﬁcally, they found that in urothelial cells, both
helical and kinase domainmutants induced increased urothelial
cell motility and migration toward a chemoattractant. In these
cells, the E545K mutant was more potent than the H1047R
mutant in inducing signaling downstream of AKT. In NIH3T3
cells, the kinase domainmutant H1047R induced higher levels
of AKT activation than the helical domain mutants, and the
latter were less able to confer anchorage-independent growth.
Collectively, the studies suggest that Pik3ca mutations af-
fecting the kinase versus helical domains also have different
functional consequences in theMOSE, with the kinase domain
mutants being more potent in stimulating epithelial hyper-
plasia. Clearly, further studies are needed to better understand
how different PIK3CA mutations might contribute to both
human and murine OvCA development and/or progression.
The hyperplastic OSE observed inPtenﬂox/ﬂox;Pik3caLSL-E545K/þ
mice is positive for CK8, WT1, and PAX8. Interestingly, we
also observed CK8, WT1, and patchy PAX8 expression in
normalMOSE.Notably, although some studies have shown that
human OSE is usually negative for PAX8,49,50 others have
shown that PAX8 is often expressed in the OSE.51 Some
investigators have suggested that the presence of PAX8þ cells
on the ovarian surfacemay be due to transfer of tubal epithelium
to the ovarian surface,52 whereas others suggest that the genes
expressed by the OSE may reﬂect a dynamic balance between
mesothelial andMullerian differentiation.53At this point, we are
unable to distinguish between these two possibilities.
In summary, we have used a murine model of type I OvCA
to examine in depth the functional effects of mutant Trp53 or
Pik3ca alleles on type I to type II progression, given the
evidence that TP53 or PIK3CA mutations may be linked to
progression and poor outcome in some women with type I
OvCA. In the mouse, Apc/;Pten/ tumors displayedmore
aggressive behavior when the tumors also harbored mutant
Trp53 or Pik3ca alleles, with shorter overall survival and
more widespread metastases. In their recent review, Romero
and Bast45 suggested that animal models that more closely
recapitulate type I and type II OvCAs are needed to facilitate
the identiﬁcation of novel therapeutic targets and to predict
response to combinations of new agents. Because the number
of women with advanced-stage type I tumors is relatively
modest, only a limited number of clinical trials that test tar-
geted agents can be performed, and careful selection of the
appropriate patients for trial enrollment will be critical. It is
easier and less expensive to test different drug combinations
and dosing schedules in animal models than in humans.
We have recently shown that Apc/;Pten/ murine model
of EOC has utility for preclinical testing of PI3K/AKT/
mTOR signaling inhibitors.31,54 Tumor growth in this model
system is inhibited by conventional chemotherapeutic agents
(cisplatin and paclitaxel), two different AKT inhibitors, and1398the mTOR inhibitor rapamycin. We are now well positioned
to test how mutations of Trp53 or Pik3ca alter tumor
response and acquisition of resistance to conventional and
molecularly targeted drugs.Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2012.12.031.References
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